Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | NMT1 | P30419 | 5/20 | 0.33 |
| ▸ | FURIN | P09958 | 5/20 | 0.33 |
| ▸ | NMT2 | O60551 | 4/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.32 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.32 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335154 | 1.00 | CPB2 (0.34) | CPB2KDM1ANMT1FURINNMT2 | |
| SCHEMBL17992368 | 0.96 | CPB2 (0.34) | CPB2KDM1ANMT1FURINNMT2 | |
| SCHEMBL22106107 | 0.92 | CPB2 (0.34) | CPB2KDM1ANMT1NMT2RCOR1 | |
| SCHEMBL22106106 | 0.92 | CPB2 (0.34) | CPB2KDM1ANMT1NMT2RCOR1 | |
| SCHEMBL17992337 | 0.91 | NMT1 (0.38) | CPB2NMT1NMT2 | |
| SCHEMBL19826070 | 0.91 | CPB2 (0.33) | CPB2 | |
| SCHEMBL21335165 | 0.90 | CPB2 (0.34) | CPB2KDM1ANMT1NMT2RCOR1 | |
| SCHEMBL21335153 | 0.88 | KDM1A (0.32) | CPB2KDM1ANMT1NMT2RCOR1 | |
| SCHEMBL17992331 | 0.86 | NPY4R (0.38) | NMT1NMT2KEAP1NPY4R | |
| SCHEMBL21335314 | 0.85 | NMT1 (0.38) | CPB2KDM1ANMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | MRPS18A, MRPL21, RRP1B | CPB2 1537/4885KDM1A 3699/4885NMT1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.